Quarterly report · Q1
4583.TEDINET S100QPID
Period2023-01-01 → 2023-03-31
Filed2023-05-11
StandardJapan GAAP
ConsolidatedNo
Data checks10 of 10 passed
Key figures · 32
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥169m | 2023-01-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥631m | 2022-01-01 → 2022-12-31 | Standalone | Net sales (5-year summary) |
| Revenue | ¥129m | 2022-01-01 → 2022-03-31 | Standalone | Net sales |
| Operating income | −¥226m | 2023-01-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | −¥487m | 2022-01-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | −¥227m | 2023-01-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥1.2bn | 2022-01-01 → 2022-12-31 | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥491m | 2022-01-01 → 2022-03-31 | Standalone | Ordinary income |
| Profit before tax | −¥226m | 2023-01-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | −¥491m | 2022-01-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | −¥228m | 2023-01-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | −¥1.2bn | 2022-01-01 → 2022-12-31 | Standalone | Net income loss (5-year summary) |
| Net income | −¥492m | 2022-01-01 → 2022-03-31 | Standalone | Profit loss |
| Total assets | ¥2.1bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥2.2bn | at 2022-12-31 | Standalone | Assets |
| Total assets | ¥2.1bn | at 2022-03-31 | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥524m | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥425m | at 2022-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.6bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥1.8bn | at 2022-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.7bn | at 2022-03-31 | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.6bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.7bn | at 2022-12-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥-4.7 | 2023-01-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-28.26 | 2022-01-01 → 2022-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-11.66 | 2022-01-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| Equity ratio | 74.3% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.2% | at 2022-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 76.3% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 48,423,500 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 48,423,500 | at 2022-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 42,409,900 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 16
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-03-31 | −¥128m |
| jpcrp040300-q1r_E26096-000Drug Discovery And Developmentreportable segment | segment profit | 2023-01-01 → 2023-03-31 | −¥194m |
| jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥169m |
| jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥169m |
| jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥96m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-01-01 → 2023-03-31 | ¥169m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-01-01 → 2023-03-31 | ¥169m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-01-01 → 2023-03-31 | −¥98m |
| Reconciling Itemsreconciling | segment profit | 2022-01-01 → 2022-03-31 | −¥111m |
| jpcrp040300-q1r_E26096-000Drug Discovery And Developmentreportable segment | segment profit | 2022-01-01 → 2022-03-31 | −¥446m |
| jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segment | revenue | 2022-01-01 → 2022-03-31 | ¥129m |
| jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segment | revenue external | 2022-01-01 → 2022-03-31 | ¥129m |
| jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segment | segment profit | 2022-01-01 → 2022-03-31 | ¥71m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-01-01 → 2022-03-31 | ¥129m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-01-01 → 2022-03-31 | ¥129m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-01-01 → 2022-03-31 | −¥375m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 321
| Item | Context | Value | Unit |
|---|---|---|---|
| Security code | FilingDateInstant | 45830 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社カイオム・バイオサイエンス | |
| Filer name in english | FilingDateInstant | Chiome Bioscience Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | false | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Current fiscal year start date | FilingDateInstant | 2023-01-01 | |
| Current period end date | FilingDateInstant | 2023-03-31 | |
| Type of current period | FilingDateInstant | Q1 | |
| Current fiscal year end date | FilingDateInstant | 2023-12-31 | |
| Previous fiscal year start date | FilingDateInstant | 2022-01-01 | |
| Comparative period end date | FilingDateInstant | 2022-03-31 | |
| Previous fiscal year end date | FilingDateInstant | 2022-12-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of reporting company (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所（グロース市場） | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数は100株であります。 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Voting rights (text) | FilingDateInstant | Text · Plus | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithFullVotingRightsOtherMember | Original text (Japanese)権利内容に何ら限定のない当社における標準となる株式であります。単元株式数 100株 | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)株式会社カイオム・バイオサイエンス | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)東京都渋谷区本町三丁目12番１号 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 10 of 10 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |